Symbols

AMRX

Amneal·NASDAQ

--(--)

AMRX fundamentals

AMRX Q4 2025 Earnings

Amneal (AMRX) released its earnings on Feb 27, 2026: revenue was 814.32M (YoY +11.47%), beat estimates; EPS was 0.21 (YoY +75.00%), beat estimates.

Revenue / YoY

814.32M

+11.47%

EPS / YoY

0.21

+75.00%

Report date

Feb 27, 2026

AMRX Earnings Call Summary for Q4,2025

Revenue Growth: 2025 revenue up 8% to $3 billion; 2026 guidance of 1-4% growth driven by Affordable Medicines (7-8% growth) and new launches.
CREXONT Success: 3% market share in first year, Phase IV data shows 3.13 hours more "Good On" time; 2026 target >100,000 patients.
Biosimilars Expansion: 6 products by 2027, including Xolair; vertical integration strategy to capture $234B biologics market.
GLP-1 Collaboration: New facilities with Pfizer position for long-term growth in $100B GLP-1 market.
Financial Strength: 2026 adjusted EPS growth 12-24%, gross margin >44%, and net leverage 3.5x.

Earnings

EPS

Revenue

Revenue & Expenses

AMRX has released its 2025 Q4 earnings report, with revenue of 814.32M, reflecting a YoY change of 11.47%, and net profit of 49.57M, showing a YoY change of 339.00%. The Sankey diagram below clearly presents AMRX's revenue sources and cost distribution.

Key Indicators

Amneal (AMRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Amneal (AMRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Amneal (AMRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Amneal (AMRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown